Severe Asymptomatic Non-alcoholic Fatty Liver Disease in Routine Diabetes Care; a Multi-disciplinary Team Approach to Diagnosis and Management
Overview
Authors
Affiliations
Objectives: To prospectively use a non-invasive algorithm to identify asymptomatic, advanced non-alcoholic fatty liver disease (NAFLD) in a secondary care diabetes clinic and to determine the short-term effect of a multi-disciplinary team (MDT) approach in a liver clinic.
Research Design And Methods: NAFLD Fibrosis Score (NFS) was calculated in 64 asymptomatic patients with type 2 diabetes. Advanced fibrosis was identified using transient elastography and confirmed with liver biopsy. In a subsequent retrospective study, 95 patients newly referred to the NAFLD MDT clinic were investigated and the impact of the MDT approach assessed.
Results: 25/64 (39.0%) of patients with diabetes had a low NFS (<-1.455). 39/64 (61.0%) patients had a high or indeterminate NFS and were referred for review in the NAFLD MDT clinic, of which 23/39 attended for assessment. 19/23 (82.6%) were diagnosed with NAFLD, of which 6/19 (31.6%) patients had a positive transient elastography (≥8 kPa). Liver biopsy confirmed advanced fibrosis in 5/6 cases, with moderate fibrosis in 1 case. In the retrospective study, 65/95 (68.4%) new referrals to the NAFLD MDT clinic had a diagnosis of NAFLD. Over a median 98 days (IQR 70-182) follow-up, there was a significant improvement in weight (-0.8 kg; P = 0.024), total cholesterol (-0.2 mmol/L; P = 0.044), ALT (alanine transmaminase, -12.5 IU/L; P < 0.001) and GGT (gammu-glutamyl transferase, -13.0 IU/L; P < 0.0001). 7/28 (25%) of patients with diabetes achieved >5% weight loss.
Conclusions: A significant proportion of asymptomatic patients attending type 2 diabetes clinics have undiagnosed advanced NAFLD fibrosis. An MDT approach to NAFLD results in short-term improvements in metabolic and liver parameters.
Tsai W, Situmorang J, Kuo W, Kuo C, Lin S, Huang C Front Pharmacol. 2025; 15():1438997.
PMID: 39850574 PMC: 11755097. DOI: 10.3389/fphar.2024.1438997.
Automated Fibrosis-4 Index: Simplifying Non-Alcoholic Fatty Liver Disease for Diabetologists.
Ismail M, Al Argan R, Elamin Y, Makki M, Alsheekh L, Alelyani J Medicina (Kaunas). 2024; 60(8).
PMID: 39202559 PMC: 11356356. DOI: 10.3390/medicina60081278.
Zijlstra M, Gampa A, Joseph N, Sonnenberg A, Fimmel C World J Hepatol. 2023; 15(2):225-236.
PMID: 36926233 PMC: 10011908. DOI: 10.4254/wjh.v15.i2.225.
The correlation between triiodothyronine and the severity of liver fibrosis.
He W, Huang C, Wang L, Su W, Wang S, Huang P BMC Endocr Disord. 2022; 22(1):313.
PMID: 36503486 PMC: 9743744. DOI: 10.1186/s12902-022-01228-8.
Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease.
Zoncape M, Liguori A, Tsochatzis E Hepatobiliary Surg Nutr. 2022; 11(4):586-591.
PMID: 36016750 PMC: 9396080. DOI: 10.21037/hbsn-22-58.